Amgen Inc (NASDAQ:AMGN) shares were slightly lower in premarket trading despite posting better-than-expected quarterly profit ...

Key Points Non-GAAP earnings per share (EPS) of $2.25 in Q2 2025 far surpassed the analyst estimate of $0.32 and rose 923% year-over-year compared to Q2 2024 (non-GAAP adjusted diluted EPS per ADS).

Amgen beat Q2 earnings and revenue expectations, raised 2025 guidance, and reported strong product sales growth across key ...

Amgen reported total revenue of $9.2 billion, topping the consensus of $8.9 billion, and non-GAAP earnings of $6.02 per share ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Novo claims the defendants are steering patients toward compounded semaglutide that has not been approved by regulators; in ...

Major indices delivered solid gains on Wednesday as market participants thumbed over a fresh batch of corporate earnings.

Eli Lilly stock tumbled Thursday on an unexpected setback for its obesity franchise, sending shares of its rival flying.

This press release is not a document produced by AFP. AFP shall not bear responsibility for its content. In case you have any questions about this press release, please refer to the contact ...

Leading the charge this morning is Smith & Nephew PLC (LSE:SN), up over 11% after the knee- and hip-replacement group ...

Avidity Biosciences stock rocketed Wednesday on a report Novartis made an attempt to buy the rare disease-focused biotech ...

In terms of quarterly earnings, drugmaker Eli Lilly hiked FY profit guidance on Thursday as it revealed Q2 revenues had surged 38% to $15.56bn. However, shares headed south in pre-market after Eli ...